Cascadian Therapeutics Inc (CASC)

3.65
0.06 1.70
NASDAQ : Health Care
Prev Close 3.59
Open 3.58
Day Low/High 3.55 / 3.65
52 Wk Low/High 0.82 / 3.89
Volume 242.46K
Avg Volume 339.00K
Exchange NASDAQ
Shares Outstanding 50.55M
Market Cap 186.54M
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cascadian Therapeutics Announces Positive Regulatory Update For Tucatinib In Europe

Cascadian Therapeutics Announces Positive Regulatory Update For Tucatinib In Europe

EMA Confirms Single HER2CLIMB Trial, If Positive, Could Support Approval

Interesting CASC Put And Call Options For February 2018

Investors in Cascadian Therapeutics Inc saw new options become available this week, for the February 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Cascadian Therapeutics Highlights Preclinical Program Presentations At The American Association For Cancer Research Annual Meeting 2017

Preclinical data from Chk1 inhibitor program and first presentation characterizing lead TIGIT antibody

Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards

Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards

Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.

Cascadian Therapeutics Announces Presentation Of Tucatinib In Combination Therapy In Patients With Cutaneous HER2+ Metastatic Breast Cancer

Cascadian Therapeutics Announces Presentation Of Tucatinib In Combination Therapy In Patients With Cutaneous HER2+ Metastatic Breast Cancer

Poster session at ESMO 2016 Congress reviews evidence of clinical activity  in patients with skin metastases

Cascadian Therapeutics Announces Proposal For Reverse Stock Split

Cascadian Therapeutics Announces Proposal For Reverse Stock Split

Special meeting to be held November 18, 2016 to seek stockholder approval

7 Stocks Under $10 Making Big Moves Higher

7 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

6 Stocks that Seth Klarman Loves

6 Stocks that Seth Klarman Loves

13F shows this mega-investor added Liberty Media and other names.